In brief
- Otsuka has finalized its acquisition of Transcend Therapeutics, the biotech firm developing TSND-201, a methylone derivative with MDMA-like effects for post-traumatic stress disorder (PTSD).
- A Phase 2 trial, published in JAMA Psychiatry, demonstrated a significant reduction in symptoms after only four weekly doses, in a protocol without formal psychotherapy but with clinical monitoring; MDMA therapy was not directly compared and preparation was not shown unnecessary.
- In June, Otsuka reported Breakthrough Therapy designation, a national voucher and phase 3 underway with estimated completion in 2027; these are neither approval nor available results.
On June 15, the Japanese pharmaceutical company Otsuka completed its acquisition of Transcend Therapeutics with $700 million paid and up to $525 million contingent on future sales, according to the release. The New York-based company is developing TSND-201, a formulation of methylone—a compound chemically related to MDMA—which achieved rapid and sustained improvements in people with severe PTSD during its Phase 2 trial.
Methylone, monitoring and limitations of masking
Methylone acts on the same dopamine, serotonin, and norepinephrine transporters as MDMA, which may explain its ability to promote neuronal plasticity and facilitate the extinction of trauma-associated fear. The key difference is that TSND-201 barely activates the 5-HT2A receptor, associated with classic psychedelics; this establishes neither absence of subjective effects nor successful masking in this trial. The protocol chose nondirective monitoring without formal psychotherapy: each session lasted at least eight hours or until effects subsided. No structured psychotherapy means neither absent supervision nor brief visits. It neither directly compared MDMA therapy nor demonstrated a solution to its masking problem: 70% of active recipients correctly identified allocation, versus 53.3% of placebo recipients. Those interested in how that protocol works can consult our Psychedelics Guide on MDMA.
Phase 2 trial data
The study, known as IMPACT-1, included 65 people with PTSD across 16 centers in the United States, the United Kingdom, and Ireland, and its results were published on February 18 in JAMA Psychiatry. Those who received TSND-201 achieved a least-squares adjusted mean reduction of 23.3 points on the CAPS-5 scale by day 64, compared to 13.6 points in the placebo group (a difference of 9.64 points; 90% confidence interval, -16.48 to -2.80; one-sided p=0.01; 60 participants in the efficacy analysis). Improvement was noticeable by the tenth day. 57.1% of those who took the drug responded to treatment compared to 19.2% in the placebo group, and 60.7% no longer met the diagnostic criteria for PTSD compared to 30.8% in the control group. Common events were headache, decreased appetite, nausea and dizziness, generally mild or moderate. All 32 active recipients reported an event; a serious seizure and severe suicidal ideation event were considered unrelated by investigators and occurred days after final dosing. No study-drug discontinuations were attributed to events; this does not establish absence of risk. According to Otsuka’s June release, FDA had granted TSND-201 Breakthrough Therapy designation in July 2025 and, in April 2026, one of its first national priority review vouchers, intended to shorten regulatory review to one or two months once the application is submitted. In June, Otsuka described EMPOWER-1 as underway and estimated completion in late 2027; current recruitment was not verified here, and this is neither available phase 3 results nor a guaranteed date.
What this implies
PTSD affects more than 13 million people per year in the United States alone and has not seen a new approved drug in nearly 25 years, so any alternative that passes Phase 3 would be significant in terms of treatment access. It is advisable to maintain the usual caution: this is still a Phase 2 trial with a modest sample size, without Phase 3 results or regulatory approval, and a corporate acquisition is not equivalent to definitive clinical validation. Furthermore, there is currently no evidence that methylone offers the same safety profile outside of a controlled trial with standardized pharmaceutical doses—something to keep in mind from a harm reduction perspective when compared to the unsupervised use of substances in the same chemical family. You can read more about these principles of informed use and risk minimization in our section on harm reduction and responsible use.
Source
- Jones A, Kelmendi B, et al. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry, February 18, 2026.
- Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Completes Acquisition of Transcend Therapeutics. Otsuka Pharmaceutical, June 15, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
